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The serine, glycine, one-carbon (SGOC) metabolic
network is implicated in cancer pathogenesis, but
its general functions are unknown. We carried out
a computational reconstruction of the SGOC
network and then characterized its expression
across thousands of cancer tissues. Pathways
including methylation and redox metabolism ex-
hibited heterogeneous expression indicating a
strong context dependency of their usage in tumors.
From an analysis of coexpression, simultaneous up-
or downregulation of nucleotide synthesis, NADPH,
and glutathione synthesis was found to be a common
occurrence in all cancers. Finally, we developed a
method to trace the metabolic fate of serine using
stable isotopes, high-resolution mass spectrometry,
and a mathematical model. Although the expression
of single genes didn’t appear indicative of flux, the
collective expression of several genes in a given
pathway allowed for successful flux prediction. Alto-
gether, these findings identify expansive and hetero-
geneous functions for the SGOC metabolic network
in human cancer.
INTRODUCTION
Serine and glycine are nutrients that fuel metabolic pathways,
including one-carbon metabolism and sulfur metabolism. This
metabolic unit, referred to as the serine, glycine, and one-carbon
(SGOC) network, provides an integration point in cellular meta-
bolism that allows for cells to achieve diverse biological functions
by converting serine and glycine into several metabolic outputs.
These outputs include building blocks for nucleotide, lipid, and
protein synthesis. They also include polyamine synthesis and
work in the maintenance of redox status as determined by gluta-
thione biosynthesis andNADPHproduction (Circu and Aw, 2010;
Fan et al., 2014; Lewis et al., 2014a;Murphy et al., 2011; Tedeschi
et al., 2013). The network also provides the substrates formethyl-
ation reactions that may have relevance to maintaining cellular
epigenetic status (Gut and Verdin, 2013; Teperino et al., 2010).
Recent work has pointed to new roles of the SGOC network in
cancer pathogenesis (Chaneton et al., 2012; Jain et al., 2012; MaCell Reet al., 2013; Maddocks et al., 2013; Scuoppo et al., 2012; Zhang
et al., 2012). Whereas a subset of cancer cells increase de novo
serine biosynthesis (Locasale et al., 2011; Possemato et al.,
2011), other cancers benefit from an increased serine and
glycine uptake rate, which allows them to metabolize these
amino acids for their biosynthetic needs (Jain et al., 2012; Mad-
docks et al., 2013). Importantly, a recent study showed that
serine, but not glycine, is critical in providing the one-carbon
units required for biosynthesis of nucleotides in some cancer
cells (Labuschagne et al., 2014). A critical role for the mitochon-
drial folate pathway in rapidly proliferating cancer cells has also
been recently elucidated (Nilsson et al., 2014). Furthermore, the
importance of one-carbon metabolism in NADPH production
through the oxidation of folates was demonstrated in cancer
cells in a number of recent studies (Fan et al., 2014; Lewis
et al., 2014a; Tedeschi et al., 2013; Vazquez et al., 2011). These
studies showed that in addition to providing cells with nucleotide
units, one-carbonmetabolism has an important role in redox bal-
ance. Despite these advances, the general coordinated usages
and different contexts in which serine and glycine flux contrib-
utes to different metabolic functions within and across cancer
types and normal tissues remain largely unknown.
Previous studies have analyzed the expression levels of meta-
bolic pathways across a variety of cancer types usingmeta-anal-
ysis approaches (Hu et al., 2013; Nilsson et al., 2014; Tedeschi
et al., 2013; Vazquez et al., 2013). These studies have identified
tumor-associated changes in gene expression across human
metabolism including one carbon metabolism. Whereas previ-
ous work has characterized expression of the SGOC network
effectively as a pathway and thus one or two data points (Hu
et al., 2013) or as a single series of individual genes (Nilsson
et al., 2014), we attempted to carefully examine with higher res-
olution the coordination and context-dependence of functionally
distinct pathways of serine utilization. We further investigate our
computational findings experimentally by tracing the metabolic
fate of serine and connecting these observations to expression
patterns in the network. Together, we identify several context-
dependent utilizations of serine in human cancers.
RESULTS
Reconstruction of the Human SGOC Network
We constructed a network that represents the metabolism of
serine and glycine through one-carbon metabolism and other
immediate pathways, including the transsulfuration pathway,ports 9, 1507–1519, November 20, 2014 ª2014 The Authors 1507
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Figure 1. Reconstruction of the Functional SGOC Network
(A) The entirety of the humanmetabolic network is first considered using a list of all metabolic genes fromKEGG. A subnetwork involving all human serine, glycine,
and one-carbon metabolism-related genes is considered and obtained from KEGG. Reaction paths from this network were used to create the final SGOC
network.
(legend continued on next page)
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that together lead to defined cellular outputs. This network,
collectively referred to as the SGOCnetwork, was generated first
by curating all human metabolic genes from the Kyoto Encyclo-
pedia of Genes and Genomes (KEGG) (Kanehisa and Goto,
2000). Each gene involved in three KEGG-defined pathways
(glycine-serine and threonine metabolism, cysteine and methio-
ninemetabolism, and folate biosynthesis) was then selected. We
subsequently included genes involved in adjacent chemical re-
actions (edges) of the selected genes (nodes), and these nodes
were then connected to the selected edges to allow for a contig-
uous sequence of chemical reactions. Finally, we pruned this
network to exclude each isolated node as well as enzymes
that carry out chemical reactions involved in other pathways
that we concluded to be nonspecific to SGOC metabolism (Fig-
ure 1A; Experimental Procedures).
As a result, the network comprises a set of 64 genes involving
core metabolic reactions and enzymes and isoenzymes (Fig-
ure 1B). Inputs of the network include de novo serine and glycine
metabolism from glucose and the import of serine and glycine
from the extracellular space. Outputs of the network include pu-
rine, pyrimidine, lipid, glutathione, redox, taurine, and methyl-
ation metabolism. In practice, the network is compartmentalized
into cytosolic/nuclear and mitochondrial components that can,
to some extent, be captured in these reaction sequences when
metabolites are shuttled in and out of the mitochondria.
Expression of the SGOC Network in Human Cancers
and Normal Tissues
Having constructed this network, we then investigated its
expression in several cancer types and corresponding normal
tissues. We considered both The Cancer Genome Atlas
(TCGA) data across breast, ovarian, lung, and colorectal cancers
(Cancer Genome Atlas Network, 2012a, 2012b; Cancer Genome
Atlas Research Network, 2011, 2012) and the Gene Expression
in Normal and Tumor (GENT) database (Shin et al., 2011) that
contains larger numbers of normal tissue samples. We chose
these cancer types for two reasons: (1) the three major types
(breast, lung, and colon) represent major sources of cancer mor-
tality, with ovarian cancer exhibiting expression patterns similar
to that of subtypes of breast cancer observed to have enhanced
requirements for serine metabolism (Locasale et al., 2011; Pos-
semato et al., 2011); and (2) each of the three major cancer types
considered has been shown to exhibit clinical response to che-
motherapies that target nodes within the one-carbon meta-
bolism network (Chabner and Longo, 2011). For each tumor
type, expression data are available across hundreds of tumors,
allowing for extensive statistical characterization.
We first assessed the global expression of the genes in the
network (Table 1; Table S1). A hierarchical clustering across the
cancer types revealed clustering based largely on tissue type
(Figure 1C) consistent with the results of principal component
analysis (PCA) (Figure S1). Major exceptions were observed for
lung cancer samples as well as a subset of breast cancers that(B) Schematic of resulting network and its decomposition into functional outputs
(C) Expression patterns of SGOC network genes across four cancer types (ov
clustering (where 100 randomly chosen samples from each cancer type from TC
(D) Cumulative density plots showing the distribution of SGOC expression levels
Cell Reclusteredwith ovarian cancer, in which case breast cancers lack-
ing estrogen receptor exhibited expression patterns indistin-
guishable from those of ovarian cancer. Next, an analysis of the
global properties of the network was considered. In ovarian, co-
lon, and lung cancers, the overall distribution of SGOC network
gene expression is shifted toward higher expression levels
compared to the levels in corresponding normal tissue (Fig-
ure 1D). However, in breast cancer, the broad range of the cumu-
lative density plot shows a higher variability in the expression
levels of SGOC genes compared to normal breast tissue (Fig-
ure 1D). In all cancer types, the distribution of SGOC expression
differed between tumor and normal (Kolmogorov-Smirnov
pvalue<2.231016).Wenext considered thevariabilitybetween
and within cancer types to further identify cancer contexts of the
network (Table 1). These contexts include high expression in one
tumor type relative to others, large variation in a single tumor type,
high expression in tumor versus corresponding normal tissue,
and high variability in tumor versus normal (Table S1). The result-
ing calculations revealed that genes predominantly involved in de
novo nucleotide synthesis pathways are overexpressed in all four
cancer types compared to the corresponding normal tissues
(Table 1). This result is in agreement with the previous literature
emphasizing the importance of nucleotide biosynthesis to rapidly
proliferating cells (Hu et al., 2012; Wilson et al., 2012). Further-
more, consistent with a recent observation (Nilsson et al., 2014),
we also observe methylenetetrahydrofolate dehydrogenase 2
(NADP+ dependent) (MTHFD2) and serine hydroxymethyltrans-
ferase 2 (SHMT2), two mitochondrial enzymes that contribute to
nucleotide metabolism, to be consistently overexpressed in can-
cers compared to corresponding normal tissues (Table 1).
Furthermore, when SGOC enzymes with a mitochondrial isoform
were compared to their cytosolic isoforms, themitochondrial iso-
formsshowedstrongerupregulation in tumors (Fisher’s exact test
p value = 0.02), demonstrating the importance of mitochondrial
compartment in tumor metabolism (Supplemental Experimental
Procedures). However, some cancer type-specific expression
patterns were also observed. For instance cystathionine beta-
synthase (CBS), serine dehydratase (SDS), and glutathione syn-
thetase (GSS) were expressed more highly in ovarian, breast,
and colon tumors, respectively (Table 1). These three genes
also showed very little within-cancer type variation in contrast
to other genes. Cross normal-tissue comparisons revealed high
expression of thymidylate synthetase (TYMS) in normal colon
and alanine-glyoxylate aminotransferase (AGXT) in normal breast
(Table 1). Together, the variation in genes within tumor types and
in comparison to corresponding normal tissues identified many
context-dependent expression patterns in the network.
Serine Utilization in the SGOC Network
After analyzing the expression of individual genes, we consid-
ered a functional analysis of the metabolic outputs of the
network. We first introduced a framework for understanding
the different metabolic fates of serine. We decomposed the(mitochondrial isoforms are shown in yellow). See also Table S2.
arian, lung, colorectal, and breast) visualized with unsupervised hierarchical
GA were used). See also Figure S1.
across four tumor types and their corresponding normal tissues (GENT).
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Table 1. SGOC Expression Analysis across Tissues
Name T-T Highest T-T Significance N-N Highest N-N Significance
T-N Overexpression
(p Value < 2.8 3 106) T-N Significance
ADC breast x+ breast x+ breast, ovary, lung , , 
AGXT1 colon x+ breast x+ lung 
AGXT2(m) breast x+ breast x+ colon, lung , 
AHCY colon x colon x+ breast, colon, lung , +, +
AHCYL1 ovary x+ breast x+ ovary, colon , 
ALAS1(m) colon x colon x+ ovary 
ALAS2(m) lung x breast x+ colon 
AMT(m) colon x ovary x —
ANPEP colon + breast x+ ovary 
ATIC colon x colon x+ breast, colon, lung +, +, +
BHMT lung x breast x+ ovary, lung , 
BHMT2 breast x+ breast x+ ovary, lung , 
CBS ovary x+ ovary breast, ovary, lung , , +
CDO1 breast x+ breast x+ colon 
CHDH(m) colon x breast x+ ovary, colon, lung , , +
CP ovary x lung x ovary, lung , +
CSAD breast x+ breast x+ —
CTH colon x+ colon x+ lung +
DHFR colon x colon x+ breast, ovary, colon, lung , , +, +
DLD(m) colon x+ colon x+ breast, ovary , 
DMGDH(m) ovary x+ breast x+ colon 
FPGS(m) ovary + breast x+ ovary, colon, lung , +, 
FTCD ovary x breast x+ ovary, colon, lung , , 
GAD1 lung x breast x+ colon, lung +, +
GAD2 lung breast x+ colon, lung , 
GAMT breast x breast x+ ovary, lung , +
GART colon x breast x breast, ovary, colon, lung , +, +, +
GATM breast x+ breast x+ lung 
GCAT(m) lung colon x breast, colon, lung , , +
GGH colon x colon x+ breast, ovary, colon, lung , , , +
GLDC(m) ovary x+ breast x+ ovary, lung , +
GNMT breast x breast —
GOT1 colon x+ colon x+ breast 
GOT2(m) colon x+ ovary x breast, colon, lung , , 
GPT colon x+ colon x+ —
GPT2 ovary x breast x+ colon, lung +, +
GSS colon x+ colon x+ breast, colon, lung , , +
IL4I1 ovary x ovary breast, ovary, colon, lung , , , +
MAT1A ovary x+ ovary x colon 
MAT2A ovary x+ lung ovary, colon +, 
MAT2B colon x breast x —
MPST(m) colon x colon x+ ovary 
MTFMT(m) colon x ovary —
MTHFD1 colon x+ breast x+ colon, lung , +
MTHFD1L(m) lung x ovary x colon, lung +, +
MTHFD2(m) lung x colon x breast, ovary, colon, lung +, +, +, +
MTHFR ovary x+ breast x —
(Continued on next page)
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Table 1. Continued
Name T-T Highest T-T Significance N-N Highest N-N Significance T-N Overexpression
(p Value < 2.8 3 106)
T-N Significance
MTHFS lung x ovary breast, colon, lung , , 
MTR ovary x+ ovary x+ colon +
NAGS(m) colon x colon lung 
PDPR(m) ovary x+ breast x+ ovary, colon , 
PHGDH ovary x breast x+ colon, lung +, 
PIPOX ovary x ovary x+ colon, lung +, +
PPCS lung ovary x breast, lung , +
PPIG ovary x+ ovary x —
PSAT1 ovary x breast x+ ovary, colon, lung +, +, +
PSPH lung ovary x breast, colon , +
SARDH(m) breast x+ breast x+ lung 
SDS breast x+ breast x+ breast, ovary, colon, lung , , , +
SHMT1 ovary x breast x+ lung 
SHMT2(m) ovary x+ ovary x breast, ovary, colon, lung +, , +, +
TYMS colon colon x+ breast, colon, lung +, , +
ALDH1L1 colon x breast x+ ovary, colon, lung , +, +
ALDH1L2(m) NA NA breast x+ ovary, colon, lung +, +, +
The SGOCgenes are listed in the first columnwithmitochondrial enzymes denoted by ‘‘m.’’ The second column shows the cancer typewith the highest
average expression across the four cancers in the study. In the significance column, Mann-Whitney-Wilcoxon p values smaller than the genome-level
Bonferroni threshold (2.83 106) are denoted by an ‘‘x’’ and effect sizes larger than 0.3 are denoted by a ‘‘+’’ sign. The fourth and fifth columns sum-
marize similar analysis across the four normal tissue types. The sixth and seventh columns summarize the results of tumor versus normal comparisons.
In the sixth column, tissue types in which a significant overexpression (p value < 2.8 3 106) was detected in tumors are listed. The seventh column
specifies corresponding effect sizes by a ‘‘+’’ if larger than 0.3 and a ‘‘’’ otherwise. NA denotes missing data. See also Table S1.SGOC network into pathways that utilize serine as an input and
achieve a distinct biological function as an output (Experimental
Procedures). We also added de novo serine biosynthesis as an
additional pathway due to its implications in cancer (Locasale,
2013). For each pathway, we analyzed the overall range of
expression (Figure 2A). It was observed that there is large
within-cancer variability in expression of pathways, especially
across different breast tumors (Figure 2A). Furthermore, mean
pathway expression was similar across cancer types for some
pathways such as methylation, whereas there were significant
differences in other pathways, including de novo serine biosyn-
thesis (Figure 2A). Next we developed an algorithm to evaluate
the expression along each functional pathway (Figure 2B). We
first decomposed each biologically distinct unit of the network
into a set of genes. Then, the mean, median, and variation of
expression for each gene comprising each pathway was
computed and statistics were evaluated across the population
of tumors (Experimental Procedures). Since the pathways varied
in length, we normalized the obtained values to the number of
genes contained in the pathway.
We considered this pathway analysis with several contrasts:
expression levels in one cancer relative to other tumor types
(T-T), variability in individual tumor (T) types, overexpression of
the pathway in tumor relative to normal tissue (T-N), expression
of the pathway in one normal tissue relative to other tissue types
(N-N), andvariability in tumor versuscorresponding normal tissue
(T-N CV). Each of these analyses provides unique information
relevant to cancer. For example, high expression in the normalCell Retissuemay indicate a predisposition for the usage of the pathway
in a particular cancer type. Furthermore, a high variability indi-
cates possible selective usage or overexpression in some
context of tumorigenesis, such as a particular mutational event.
Due to the tremendous heterogeneity within cancer types, a
high within-cancer-type variability is important to know, since it
implies that different subpopulations of samples behavedifferen-
tially with respect to a certain pathway, which suggests their po-
tential use as biomarkers, provides further context for the use of
the pathway, and finally possibly yields some predictive capacity
for evaluating the response to agents that target the pathway. A
comparison across tumor tissues shows that several pathways
are overexpressed relative to other tumors with breast and
ovarian cancer exhibiting higher expression of specific compo-
nents of sulfur-related metabolism (Figure 2C). High variability
across each cancer type was observed throughout the network,
but the taurine,methylation, andNADPHpathways showedhigh-
est variability compared to other pathways (Figure 2D). However,
when comparing expression in normal and tumor tissue, only
routes related to nucleotide and redox metabolism were
commonly upregulated in tumors, consistent with previous anal-
ysis of individual genes (Figure 2E). Interestingly, in comparing in-
dividual genes and pathways, we found that high relative levels of
expression in one normal tissue did not necessarily overlap with
high relative levels of expression in tumor tissue, indicating shifts
in metabolism that are not directly due to differences in tissues of
origin (Figure 2F). This observation is also apparent in comparing
the variability in expression of tumor and normal cancer typesports 9, 1507–1519, November 20, 2014 ª2014 The Authors 1511
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Figure 2. Functional SGOC Pathway Utilization across Four Cancer Types
(A) Boxplots showing average pathway expression across four cancer types (TCGA). Horizontal lines denote are median pathway expression. Boxes represent
10th and 90th percentiles, and whisker lines denote the range of expression values.
(B) Summary for quantification of pathway utilization analyses.
(C–G) Barplots denoting the collective expression of a given pathway route in the SGOC network. (C) Pathways hyperutilized in a single cancer type relative to
others. (D) Pathways exhibiting high variation within cancer types. (E) Pathways overexpressed in tumor versus corresponding normal tissue. (F) Pathways highly
expressed in one normal tissue relative to others. (G) Pathways with high variation in tumor versus normal tissue.(Figure 2G). Altogether, these findings identify relationships of
context-dependent utilizations of the SGOC network.
Co-occurrence of Pathway Utilization within the
Network
Since, in metabolism, the output of one branch of the network is
coupled to the output of all other branches, we hypothesized
that therecouldexist correlations in theexpressionofsetsofgenes
leading to metabolic outputs of the network. To investigate this
possibility, we computed a similarity matrix for each of the cancer
types. Clustering of each similarity matrix revealed co-occurring
expression patterns in each cancer type, suggesting coordinated
utilization of certain enzymes (Figure3A). A global analysis of these
pairwise correlations revealed that the genes in theSGOCnetwork
were significantly more correlated compared to randomly chosen
genes as revealed by quantile-quantile (QQ) plots (Figure 3B). This
reports a demonstration of coordinated expression of metabolic
genes in a defined metabolic pathway in humans.
Next, we considered the normalized mean expression of the
pathway routes that illustrated the extent of co-occurrence in1512 Cell Reports 9, 1507–1519, November 20, 2014 ª2014 The Autthe network (Figure 3C). When assessed across the four cancer
types, it is found that correlations emerge along specific path-
ways. Surprisingly, many of these correlations were largely found
to be independent of tissue type, demonstrating the existence of
unique metabolic programs within each tissue. A core group of
pathways involving glutathione, NADPH, and nucleotide meta-
bolism show correlations in their expression, suggesting that a
coupling between de novo nucleotide and redox metabolism
occurs. De novo serine synthesis correlated only with cysteine
metabolism in some cancer types, indicating that the condensa-
tion of serine and entry into the transsulfuration pathway is a
major usage of serine in cells with enhanced de novo serine
biosynthesis. Also, in all cancer types, taurine and nucleotide
metabolism anticorrelated with one another, indicating that their
usages are orthogonal in cancers.
Serine-Derived Metabolic Fluxes in the Network
Gene expression in human clinical samples offers an unbiased
assessment of the expression of the network in cancer. How-
ever, gene expression does not necessarily determine metabolichors
DA B C
Figure 3. Correlations across Reaction Paths in the SGOC Network
(A) Hierarchically clustered similarity matrices for four cancer types based on pairwise Spearman correlations. Modularity in the coexpression network is
apparent.
(B) Overview of algorithm that collapses coregulated genes into reaction paths.
(C) Quantile-quantile (QQ) plots showing p values from gene-gene spearman correlations in SGOC compared to randomly chosen pair of genes.
(D) Correlations in expression of transcripts in one pathway in reference to another. Results are organized by hierarchical clustering using Spearman correlations
in linkage similarities.phenotype that ultimately involves metabolic flux or the rate of
flow of a metabolite from one point in the network to another.
To investigate the relationship of metabolic flux with gene
expression, we first developed a 13C serine-based isotopomer
mass spectrometry method. A panel of cancer cells was incu-
bated with 13C-labeled serine, and relative abundances of all
mass isotopomers (molecules differing only in the extent of their
isotopic composition) of each metabolite were measured from
the integrated ion current. Uniformly labeled serine (U-13C-
serine) was present in the media in a 1:1 proportion with respect
to unlabeled serine in the culture medium. Therefore, at steady
state, as expected, a substantial portion of the serine is unla-
beled (Figure S2). Furthermore, M+1 glycine was detected near
the natural abundance level in our experiment (Figure S2), sug-
gesting that glycine cleavage does not happen in reverse at a
substantial rate. The eight human colon cancer cell lines usedCell Rein this study consistently showed labeling of glutathione and
de novo purine and thymidine synthesis intermediates, while lit-
tle or no label was detected on methionine, pyruvate, alanine,
betaine, and taurine (Figures 4A and S3). Since gene expression
is available for each of these cell lines, we could then ask to what
extent patterns in gene expression could be related to these
isotope patterns. Using abundance ratios of mass isotopomers
as surrogates for the corresponding fluxes, we studied correla-
tions between labeling patterns and gene expression first at
the single gene level and then at the level of pathways (Figure 4B).
We asked whether gene expression within the network could
predict isotope-labeling patterns. We found that the expression
of individual genes in the SGOC network could, to some extent,
predict fluxes (Figure 4C; false discovery rate [FDR] q value =
0.15). Notably, results from a Fisher’s exact test indicate that
gene expression at the pathway level is more strongly correlatedports 9, 1507–1519, November 20, 2014 ª2014 The Authors 1513
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Figure 4. Flux Analysis of Serine Metabolism
(A) Abundance ratios for labeled isotopomers detected across the eight colon cancer cell lines. Errors are obtained from SDs (n = 3 independent biological
experiments).
(B) Overview of mass-isotopomer analyses.
(C) Histogram of the number of significant correlations between labeled SGOCmetabolite isotopomers and expression of randomly selected networks of genes.
Expression of SGOC genes shows a higher-than-random correlation (FDR = 0.15).
(D) Quantification of the frequency of significant correlations between SGOC expression and isotopomer labeling at the single-genes level versus the pathway
level using a Fisher’s exact test. See also Figure S3.with fluxes compared to the single-gene level (Figure 4D). In
summary, results from these data indicate that fluxes can be
determined directly to an extent from gene expression in cancer
cells, but this requires knowledge of the overall expression of the
pathway. This study provides an example of the relationship be-
tween gene expression and flux in a mammalian system.
Interaction between De Novo Nucleotide and
Glutathione Biosynthesis
We then further investigated the relationship between de novo
nucleotide metabolism and glutathione synthesis (Figure 5A) in
colorectal cancer cells. We considered the relationship between
thymidine and glutathione synthesis, purine and glutathione syn-
thesis, and purine and thymidine synthesis (Figure 5A). In each
case, the expression levels of key genes in the pathway provided
little information about the pathway relationships. However,
when comparing pathway expression, strong correlations in
nucleotide synthesis and glutathione biosynthesis exist. This
phenomenon was observed both in TCGA colon cancer data as1514 Cell Reports 9, 1507–1519, November 20, 2014 ª2014 The Autwell as in gene expression data from the eight colon cancer cell
lines in the study. Experimentally, this result is also apparent in
that labeling of de novo nucleotide synthesis intermediates was
highly correlated with glutathione labeling (Figure 5A). Together,
these findings point to a model where increases in nucleotide
biosynthesis are coupled to flux to glutathione synthesis,
whereas other pathway routes from serine are not correlated
with nucleotide synthesis (Figure 5B). Since NADPH synthesis
is coupled to the redox balance of oxidized and reduced gluta-
thione, this finding provides a possible connection to a recent
finding indicating that one-carbon metabolism is a major source
ofNADPH in cells (Fanet al., 2014). In fact,wealso observeapos-
itive association between NADPH synthesis and nucleotide and
glutathione synthesis at the pathway level (Figure S4).
Mathematical Modeling of Pathway Fluxes
Although labeling patterns can sometimes be used to infer the
extent of flux through a pathway, in general, this is not always
the case. Fluxes ultimately are required to be estimated fromhors
AB
Figure 5. Interaction between De Novo Nucleotide and Glutathione Synthesis
(A) Thymidine and glutathione (top). The left plot shows weak association between TYMS and GSS expression (R2 = 0.094). The middle plot shows significantly
higher correlation between thymidine and glutathione at the average pathway expression level (R2 = 0.53). The right plot shows association between glutathione
and thymine label ratios (R2 = 0.35). Purine and glutathione (middle). The left plot showsweak association between phosphoribosylglycinamide formyltransferase
(GART) and GSS expression at the single-gene level (R2 = 0.01). The middle plot shows significantly higher correlation between purine and glutathione at the
average pathway expression level (R2 = 0.54). The right plot shows association between glutathione and S-adenosyl-methionine (SAM)-label (a purine inter-
mediate) ratios (R2 = 0.44). Thymidine and purine (bottom). The left plot shows weak association between TYMS and IMP cyclohydrolase (ATIC) expression at the
single-gene level (R2 = 0.001). The middle plot shows significantly higher correlation between thymidine and purine at average pathway expression level (R2 =
0.55). The right plot shows association between inosine-monophosphate (IMP)-label (a purine intermediate) and thymine-label ratios (R2 = 0.67).
(B) Schematic showing serine metabolic outputs. Results from tracing serine in vitro suggest a simultaneous flux going through de novo nucleotide and
glutathione synthesis pathways (green arrows) in the colon cancer cell lines studied when little or no flux goes from serine to the other pathways. Direct NADPH
labeling could not be assayed in our experimental setup using 13C-serine. See also Figure S4.network models that account for the isotope patterns. We there-
fore considered a mathematical model of the mass-isotopomer
distributions (MIDs) to estimate quantitative values for the fluxes
in the network (Figure 6A; Experimental Procedures). A two-
compartment serine-glycine-methylenetetrahydrofolate (Ser-
Gly-meTHF) metabolic model was used to fit experimental 13C
MIDs of the SGOC network to determine metabolic fluxes
involving transport and exchange relative to extracellular serine
transport (Ftr ser = 1). The metabolic network includes cellular
serine production via de novo synthesis from 3-phosphoglyc-
erate, extracellular serine uptake; reversible cytosolic SHMT1Cell Reand mitochondrial SHMT2 fluxes; mitochondrial glycine cleav-
age system (GCS) activity; serine, glycine, and meTHF (formate)
exchange fluxes between cytosolic and mitochondrial compart-
ments; dilution fluxes for cytosolic and mitochondrial one-car-
bon metabolite pool represented in the model by meTHF; de
novo and salvage formation pathways for adenine (Ade repre-
senting purines) and thymidine (Thd representing pyrimidines);
and glutathione production flux. An analysis of the fluxes across
each cell line provided direct quantitative information about the
distribution of fluxes across the network (Figure 6B). For
example, flux from glycine to serine varied over an order ofports 9, 1507–1519, November 20, 2014 ª2014 The Authors 1515
A C
D
B
E
Figure 6. Mathematical Modeling Estimates Fluxes in Purine and Pyrimidine Synthesis Pathways
(A) Schematic of the model that was used for flux estimation. Serine, glycine, and formate are shuttled in and out of the mitochondria, whereas folate is not. Plots
show mass-isotopomer distributions (MIDs) for metabolites that were detected experimentally. Fluxes that were estimated are labeled by green rectangles.
(B) Barplots of estimated fluxes with respect to the serine transport flux (Ftr ser = 1) across the eight cell lines. (Fshmt1+: forward flux through SHMT1; Fshmt1:
reverse flux through SHMT1; Ftr-gly: glycine transport flux; Fx-ser+: serine exchange flux; Fphgdh: de novo serine synthesis flux; Fshmt2+: forward flux through
SHMT2; Fx-methf+: meTHF exchange flux through formate; Fthd-dn: de novo thymidine synthesis flux; Fade-dn: de novo adenine synthesis flux).
(C) Purine and thymidine pathways are correlated. Estimated fluxes for de novo thymidine and adenine synthesis are positively associated (R2 = 0.14) (left).
Expression of the purine pathway is positively correlated with that of the de novo thymidine pathway (R2 = 0.4) across the eight colon cancer cell lines (right).
(D) Glutathione and thymidine pathways are correlated. Estimated fluxes for de novo thymidine and glutathione synthesis (SHMT1+) are positively associated
(R2 = 0.39) (left). Expression of the glutathione pathway is positively correlated with that of the de novo thymidine pathway (R2 = 0.7) across the eight colon cancer
cell lines (right).
(E) Glutathione and purine pathway correlations. Estimated fluxes for de novo adenine and glutathione synthesis (SHMT1+) are positively associated (R2 = 0.42)
(left). Expression of the glutathione pathway is positively correlated with that of the de novo purine pathway (R2 = 0.28) across the eight colon cancer cell lines
(right). See also Figure S2 and Table S3.magnitude suggesting that some cells may be able to compen-
sate for differences in serine availability through the uptake of
glycine. Across the cell lines, results from the analyses of esti-
mated fluxes show a positive relationship between the de novo
purine and thymidine pathway fluxes consistent with the
pathway expression levels across the eight cell lines (Figure 6C).
Furthermore, using estimated flux through the enzyme SHMT1
as a surrogate for glutathione production flux, a positive relation-
ship is detected between glutathione and thymidine synthesis at
both the flux level and the pathway expression level (Figure 6D).1516 Cell Reports 9, 1507–1519, November 20, 2014 ª2014 The AutSimilarly, purine biosynthesis shows a positive association with
glutathione production (Figure 6E). Together, these findings
identify the heterogeneity of pathway fluxes across the network
in a set of cell lines and provide confirmation of correlations that
exist in the utilization of serine for specific metabolic functions.
DISCUSSION
Our findings present the first comprehensive systems-level
analysis of the expressions patterns, metabolic fluxes, andhors
interrelationships of serine metabolizing pathways in numerous
cancer contexts and together delineate the likely roles of the
SGOC network in several cancer types. While there is no general
global overexpression of the entire network in cancer as found in
other pathways such as glycolysis, the expression of the network
differs in more complex ways. Heterogeneity is strikingly
apparent with, for example, breast cancers showing both overall
under- and overexpression of multiple pathway components.
Components contributing to nucleotide synthesis are commonly
upregulated as previously reported (Hu et al., 2013; Jain et al.,
2012), but other pathways exhibit no general features of over-
and underexpression across cancer types. In normal tissues,
many of these components are constitutively expressed with
high variability, suggesting that the usage of a particular compo-
nent in the normal tissue may confer predisposition of its usage
in cancer.
When considering coexpression of the network, strong corre-
lations in individual genes and expression of the pathways were
observed. Themost common coexistence was the expression of
genes contributing to nucleotide metabolism, glutathione, and
NADPH synthesis. This was also observed in direct measure-
ments of pathway fluxes for glutathione and nucleotides. Since
glutathione is the essential component of cellular redox mainte-
nance, concomitant synthesis of glutathione and nucleotides
likely provides a redox environment necessary for nucleotide
synthesis and repair. In fact, several studies in plants have
demonstrated that redox regulation by glutathione has an impor-
tant role during nucleotide synthesis and cell division (Belmonte
et al., 2003, 2005; Stasolla, 2010). By performing coexpression
analyses on the serine pathways, we provided insights into the
biology of the SGOC network in cancer. Our study finds that
association of glutathione synthesis with nucleotide synthesis
appears in the context of human cancer and could suggest
that cancer cells utilize a redox balance mechanism in parallel
to the upregulation of biosynthetic pathways.
Gene expression measurements are typically thought to not
be useful surrogates in cells for flux measurements that are the
ultimate phenotypes of interest in studying metabolism. How-
ever, we show that pathway-level gene expression to a large
extent in the SGOC network can be used as a predictor of exper-
imentally measured fluxes. This is a very important finding in
general given the wealth of publically available gene expression
data and the technical limitations associated with performing
large-scale metabolomics analyses on human tumor samples.
Therefore, this work hopefully provides motivation for further
comparative analysis of gene expression and flux distributions
in biological samples.EXPERIMENTAL PROCEDURES
Cell Culture and Metabolite Extraction
Colon cancer cells (SW620, SW480, HCT8, HT29, HCT116, NCI-H508, SW48,
and SW948) were cultured as previously described (Liu et al., 2014). For 13C-
serine-tracing experiments, cells were seeded in six-well plate at a density
of 2 3 105 to 5 3 105 cells per well. After overnight incubation in 37C with
5% CO2, full growth media were removed, and cells were washed with 2 ml
PBS before the addition of RPMI media supplemented with 10% dialyzed
and heat-inactivated fetal bovine serum, 100 U/ml penicillin, 100 mg/ml strep-
tomycin, and 13C-U-serine (3 mg/100 ml medium; Cambridge Isotope Labora-Cell Retory) such that in the final medium, 50% of serine is 13C labeled. After a 24 hr
incubation, the cells were harvested as previously described (Liu et al., 2014).
Mass Spectrometry and Liquid Chromatography
The qExactive mass spectrometer (QE-MS) coupled to liquid chromatography
(LC; Ultimate 3000 UHPLC) was used for metabolite separation and detection
as previously described (Liu et al., 2014). Raw data collected from LC-QE MS
were processed with Sieve 2.0 (Thermo Scientific). Relevant instrument pa-
rameters are contained in a previous work (Liu et al., 2014).
Network Construction and Gene Expression Analyses
The network reconstruction was carried out using the Metscape plugin for
Cytoscape (Gao et al., 2010). The SGOC network was generated first by
curating all human metabolic genes from KEGG (Kanehisa and Goto, 2000).
All genes involved in the KEGG-defined pathways glycine, serine, and threo-
nine metabolism; cysteine and methionine metabolism; and folate biosyn-
thesis were selected. We subsequently included genes involved in adjacent
chemical reactions (edges) of the selected genes (nodes), and these nodes
were then connected to the selected edges to allow for a contiguous sequence
of chemical reactions. Finally, we manually excluded all genes that involve
non-pathway-specific chemical reactions that thus take part in many meta-
bolic pathways, implying that their function need not be confined to 1-C meta-
bolism (reactions including ATP dependent; tRNA synthesis; methylation;
CoA; CO2 and NH3; aldehyde dehydrogenases; pyruvate metabolism) (see
Table S2 for the complete list of genes excluded).
Gene expression across human tumors was analyzed using level 3 TCGA
mRNA data (Cancer Genome Atlas Network, 2012a, 2012b; Cancer Genome
Atlas Research Network, 2011, 2012). Data from AgilentG4502A microarray
chips were collected for all TCGA breast (BRCA), ovarian (OV), colon
(COAD), and lung (LUSC, LUAD) samples corresponding to four cancer types.
Level 3 data contain combined probe signals for each gene and samples were
LOWESS normalized using a reference RNA sample (cy5/cy3) (Yang et al.,
2002); therefore, poor probe binding was accounted for by reporting the ratio
of mRNA from sample to that of the standard. Mean and median expression
levels were calculated for each of the 64 genes in the SGOC network across
each cancer type.
For evaluating high expression of one cancer type relative to other cancer
types, we considered the following. For each gene, the cancer type that had
the highest median expression was grouped (‘‘high expression’’) and all sam-
ples from the other three cancer types were pooled into one group (‘‘low
expression’’). The Mann-Whitney Wilcoxon (Wilcoxon) test was then per-
formed to compare gene expression between the ‘‘high-expression’’ versus
‘‘low-expression’’ groups. The Bonferroni method for multiple hypothesis
correction was then applied to determine the significant p values. Effect sizes
for the Wilcoxon test are calculated as r = Z/sqrt(N), where N is the total num-
ber of samples and Z is the Z score for the Wilcoxon test. Genes with a signif-
icant p value but a small effect size (r < 0.3) were also considered insignificant.
The result of this analysis is a set of genes highly expressed in one cancer type.
For tumor versus normal comparisons, Affymetrix U133Plus2 expression
data from the GENT data set were used for breast, ovarian, colon, and lung
cancer as well as normal tissue samples. The data were preprocessed using
the MAS5 algorithm and then normalized to a target density of 500 to correct
for batch effects according to GENT specifications (Shin et al., 2011). Each
cancer type was compared to its corresponding normal tissue using the
same statistical approach (Wilcoxon test with Bonferroni and effect size cor-
rections). Comparisons of expression in one normal tissue type relative to
other normal tissue types were conducted on these data using the same sta-
tistical criterion.
For ananalysis of variability in expression, thecoefficient of variation (CV)was
calculated for each gene across each tissue type. CV comparisons for each
case were carried out using the same criteria starting with the Wilcoxon test.
Pathway Definitions and Analysis
We considered the amino acid serine as the input source of one-carbon units
to the SGOC network and decomposed the network into biochemical path-
ways that consume serine in different reactions and result in a distinct biolog-
ical output.ports 9, 1507–1519, November 20, 2014 ª2014 The Authors 1517
The enzymes in each of the pathways from serine metabolism are as follows
(mitochondrial isoforms are denoted by ‘‘m’’):methylation, SHMT1/SHMT2(m) –
MTHFR- MTR/BHMT/BHMT2- MAT1A/MAT2A/MAT2B; thymidine, SHMT1/
SHMT2(m) – AMT(m)-TYMS- DHFR; purine, SHMT1/SHMT2(m) - MTHFD1/
MTHFD2(m)/MTHFD1L(m) - ATIC/GART;NADPH,SHMT1/SHMT2(m) -MTHFD1/
MTHFD2(m)/MTHFD1L(m) - ALDH1L1/ALDH1L2(m); alanine, AGXT1/AGXT2(m);
glutathione, SHMT1/SHMT2(m) – GSS; cysteine, CBS- CTH; taurine, CBS-
CTH- CDO1- CSAD; betaine and holine, SHMT1/SHMT2(m) - CHDH(m); and
pyruvate, SDS.
To compare these pathways in reference to the statistical analysis that we
conducted for each gene, we considered an overall pathway score (frequency
of occurrences). For each pathway, the number of significant genes, normal-
ized to the number of genes in that pathway, was computed for each of the sta-
tistical analyses that we performed. Results are reported in Figure 2.
For the analysis of network covariance, similarity matrices were constructed
based on pairwise Spearman correlations between expression levels of the 64
SGOCmetabolic genes across each one of the four cancer types (lung, breast,
colon, and ovarian) in the study. In order to visualize these correlations in the
context of serine-fate pathways, average pathway expression levels were
measured for all tumor samples in study, and similarity matrices were made
based on Spearman correlations between average pathway expressions
separately in each cancer type. All clustering calculations were carried out us-
ing the Gene-E package (Broad Institute; http://www.broadinstitute.org/
cancer/software/GENE-E/).
For comparison of pairwise correlations between expression levels of SGOC
genes to that expected by chance, we used a randomization method. We
randomly picked 64 genes from the genome and calculated pairwise correla-
tions of those genes and repeated this for 100 iterations. Finally, we used the
average of sorted p values form the 100 iterations and plotted the results
against the sorted p values from SGOC pairwise correlations separately for
each cancer type (quantile-quantile plots).
Finally, mRNA expression data for the eight colon cancer cell lines in study
were obtained from the Broad Institute Cancer Cell Line Encyclopedia (Barre-
tina et al., 2012) and similar SGOC pathway expression analyses were per-
formed on the data for comparisons with isotope labeling and flux data.
Correlation between expression levels of SGOC genes with label ratios in
serine, glycine, thymidine, glutathione, and IMP (representing purines) were
calculated across the eight cell lines. As a control, label ratios were also corre-
lated with expression of same-size sets of genes randomly picked from the
genome. A histogram of all significant p values (p < 0.05) was generated
from the results of the 500 simulations. Furthermore, gene expression at the
pathway level (average across pathways shown) was also correlated with de-
tected isotope enrichments. Single genes and pathways were associated with
fluxes by plotting the percent of significant correlations (p value < 0.05) be-
tween gene expression and label ratios for each case. All calculations were
carried out using R (http://www.R-project.org/).
13C Mass-Isotopomer Distribution Model
A two-compartment (mitochondria and cytosol) serine-glycine-methylenete-
trahydrofolate (Ser-Gly-meTHF) flux model was used to fit experimental 13C
MIDs of the SGOC-associated metabolites to determine intercellular meta-
bolic fluxes and transport and exchange fluxes relative to extracellular serine
transport flux. The model was formalized using two types of mass balance
equations: (1) mass balance for total metabolite concentration, and (2) 13C
mass-isotopomer mass balance for labeled metabolites based on the network
depicted in Figure 6A and corresponding atom distribution matrices. MID
equations were derived in the similar manner as equations for bonded cumu-
lative isotopomers as described previously (Shestov et al., 2012). In terms of
the ordinary differential equations, the model describes the rates of loss and
creation of particular labeled and unlabeledmetabolite that forms after incuba-
tion of labeled serine in extracellular media. Those equations are based on the
flux balance of metabolites and take the general form (e.g., for parallel unimo-
lecular reactions):
½MdmðiÞ
dt
=
X
j
FjsjðiÞ 
 X
k
Fk
!
mðiÞ; (Equation 1)1518 Cell Reports 9, 1507–1519, November 20, 2014 ª2014 The Autwhere metaboliteM is downstream of another metabolites Sj. The total outfluxP
Fk balances total influx
P
Fj. [M] represents the total pool size of metabolite
M, while m(i) and sj(i) represent the I mass-isotopomer fraction of metabolite M
(M+Imass isotopomer) and metabolite Sj (S+Imass isotopomer), respectively.
The number of labeled C atoms in M molecule, I, changes between 0 and N,
where N is the total number of C atoms in metabolites. At steady state, the
left term of Equation 1 is equal to zero, resulting in a set of algebraic equations.
For labeled [U-13C] serine experiments in RPMI medium, the fitted experi-
mental steady-state mass isotopomers (combined cytosolic and mitochon-
drial) were four isotopomer forms of serine, three forms of glycine, four forms
of glutathione (which serve as a readout for cytosolic glycine patterns), three
forms of thymidine, and six isotopomer forms of adenine, together making a
total of 20 steady-state mass isotopomers. Thymidine and adenine iso-
topomers reflect pyrimidine and purine metabolism, respectively. Eleven
fluxes were determined relative to serine transport flux, which are represented
in Table S3: de novo serine synthesis; two unidirectional rates for reversible
cytosolic and mitochondrial SHMT fluxes; unidirectional glycine uptake flux;
intercompartmental serine, glycine, and one-carbon pool (meTHF) exchange
fluxes; GCS activity; and mitochondrial dilution flux for meTHF due to dime-
thylglycine and sarcosine contribution. Also, the fraction of the de novo thymi-
dine and adenine production along with salvage contribution was calculated.
For each metabolite MIDs, 13C natural abundance of 13C isotope (1.08%) was
taken into account. There was no need to correct for 15N natural abundance
(0.38%) due to the mass resolution used (70,000) that is able to separate
13C and 15N for the molecules considered. Solving a system of nonlinear differ-
ential equations in terms of whole/fragmented mass isotopomers, with the
Runge-Kutta fourth-order procedure (MATLAB), yields time courses for all
possible 13C mass isotopomers (e.g., serine and glycine). A quadratic cost
function was used to quantify differences between measurements and esti-
mated results for labeled steady-state data and to select the corresponding
vector of fluxes that minimizes the cost function in 13C serine experiments us-
ing a simplex algorithm. Mean-square convergence was confirmed by veri-
fying that goodness-of-fit values were close to expected theoretical values.
To overcome potential local minima, we used several sets of initial random
fluxes.
We estimated errors for the obtained values using a Monte Carlo simulation
method as previously described (Shestov et al., 2007). Initial values for all pa-
rameters were chosen close to the HCT116 cell line fluxes as a reference cell
line. 13C mass-isotopomer values for Ser, Gly, GSH, Thd, and Ade were then
generated by solving differential equations describing the model with initial
value of fluxes. For each Monte Carlo run, random Gaussian noise with
mean of zero and SD of s = 0.01 was added to the steady state of these 13C
mass isotopomers. Finally, the MIDs for each metabolite were computed
and used for fitting with the SGOCmetabolicmodel to obtain the values of rela-
tive metabolic fluxes. This procedure was repeated 500 times to obtain histo-
grams for each parameter. SDs are reported in Table S3.SUPPLEMENTAL INFORMATION
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